Miranda, Marissa C.

HRN: 22-07-18  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/17/2022
CEFTAZIDIME 1GM (VIAL)
10/17/2022
10/24/2022
IV
1g
Q8h
Cap Mr
Waiting Final Action 
10/17/2022
AZITHROMYCIN 500MG TABLET (TAB)
10/17/2022
10/21/2022
PO
500mg
OD
Cap MR
Waiting Final Action 
10/17/2022
CEFTAZIDIME 1GM (VIAL)
10/17/2022
10/23/2022
IV
2grams
Q8hrs
Sepsis Probably Secondary To HAP
Waiting Final Action 
10/24/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/24/2022
10/31/2022
IV
4.5g
Q8H
CAP-MR;PTB
Waiting Final Action 
10/24/2022
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
10/24/2022
10/31/2022
IV
750mg
OD
CAP-MR
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: